Pregabalin Capsule
Product Images NDC 50090-6504

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 50090-6504). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500906504)

FDA Label Image

Equation (Pregabain Gault Equation)

FDA Label Image

Fig-01 (Pregabalin Figure 01)

This text provides the percentage of patients improved with the use of Pregabalin in three different dosages and a placebo. It also includes the percentage improvement in pain from baseline.*

FDA Label Image

Fig-02 (Pregabalin Figure 02)

This appears to be a graph or chart showing the percentage of patients who have improved after taking Pregabalin 100 mg three times a day versus a placebo. The graph also shows the recorded percentage improvement in pain from baseline.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

This is a chart showing the percentage of patients who improved with different doses of Pregabalin and a placebo, based on their pain levels from a baseline.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

This is a chart showing the percentage of patients who improved after taking Pregabalin at different doses (100mg and 200mg three times a day) and a placebo. The chart also shows the percentage improvement in pain from the baseline, ranging from 10% to 100%.*

FDA Label Image

Fig-05 (Pregabalin Figure 05)

The given text describes a chart showing the percentage of patients who improved with different doses of Pregabalin and Placebo. It also shows the percentage improvement in pain from baseline for each treatment.*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

This document appears to be a statistical data table showing responder rates for different treatment regimens in two different studies (E1 and E3), with different dosages (50mg/day, 150mg/day, 300mg/day, and 600mg/day) for a medication, with "BID" and "TID" indicating frequency of treatment administration, and "Placebo" indicating a control group. The responder rate ranges from 9% to 60%, and there are statistically significant results indicated by an asterisk (*) when compared to placebo.*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

FDA Label Image

Fig-09 (Pregabalin Figure 09)

This is a graph showing the percentage of patients who experienced an improvement in pain from the baseline after taking different daily doses of pregabalin and a placebo. The x-axis shows the percentage of improvement in pain and the y-axis shows the percentage of patients who experienced that level of improvement. The graph shows that higher doses of pregabalin resulted in a greater percentage of patients experiencing an improvement in pain compared to a placebo.*

FDA Label Image

Fig-10 (Pregabalin Figure 10)

FDA Label Image

Fig-11 (Pregabalin Figure 11)

The text describes a graph showing the percentage of subjects who have improved from baseline to week 12 in a study using Pregabalin compared to Placebo. It shows the percentage of improvement from 0 to 100, with intervals of 10, on the x-axis, while the y-axis represents the percentage of patients improved. The graph shows that Pregabalin improves outcomes in more patients compared to placebo.*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

FDA Label Image

Str (Pregabalin Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.